This announcement is a separate document:
北京市金杜律师事务所关于荣昌生物制药（烟台）股份有限公司2023 年第二次临时股东大会、 2023 年第一次 A 股类别股东大会及 2023 年第一次 H 股类别股东大会法律意见书
Legal Opinions of Beijing Jindu Law Firm on the 2023 Second Extraordinary General Meeting of Shareholders of Rongchang Biopharmaceuticals (Yantai) Co., Ltd., the first Class A Shareholders\' Meeting in 2023, and the First Class H Shareholders\' Meeting in
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.